User login

Fetzima Approved for Depression

In July 2013, the FDA approved the SNRI Fetzima (levomilnacipran) for major depressive disorder (MDD) in adults (Forest Laboratories, Inc). The efficacy of Fetzima at doses 40 mg to 120 mg once daily was established in three, eight-week, randomized, double-blind, placebo-controlled studies in adults diagnosed MDD.

All editorial content is peer reviewed by the editorial board. Dr. Albucher, Dr. Balt, Dr. Gardiner, Dr. Goldberg, Dr. Lyman, Dr. Megna, Dr. Mick, Dr. Posternak, Dr. Spielmans, and Dr. Zuckerman have disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity. Dr. Balt discloses that his spouse is employed as a sales representative for Otsuka America, Inc.

TCPR Continuing Education
Accredited/Approved/Accepted by:

ACCME

AMA

APA

ABPN

ANCC

Search

Search this site:

Follow Us

Drug Metabolism in Psychiatry

It's here! Click here to purchase our new book "Drug Metabolism in Psychiatry: A Clinical Guide"